Predictive resistance factors  in lung cancer patients treated with Nivolumab. Retrospective study.

CONCLUSION: This study enriches data about immunotherapy in real-life in NSCLC. Prognostic resistance factors still seem complicated to identify. The high rate of taxane responders in post immunotherapy in this retrospective cohort support the use of taxane in therapeutic escape.
PMID: 33358747 [PubMed - as supplied by publisher]

Source: Bulletin du Cancer - December 24, 2020 Category: Cancer & Oncology Authors: Bernichon E, Tissot C, Bayle-Bleuez S, Rivoirard R, Bouleftour W, Forest F, Tinquaut F, Mery B, Fournel P Tags: Bull Cancer Source Type: research